Novel CXCR3 antagonists with a piperazinyl-piperidine core

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 17, 2009, Pages 5205-5208

  McGuinness, Brian F ^a   Carroll, Carolyn DiIanni ^a   Zawacki, Lisa Guise ^a   Dong, Guizhen ^a   Yang, Cangming ^a   Hobbs, Doug W ^a   Jacob Samuel, Biji ^a   Hall III, James W ^a   Jenh, Chung Her ^b   Kozlowski, Joseph A ^b   Anilkumar, Gopinadhan N ^b   Rosenblum, Stuart B ^b  

^a Ligand Pharmaceuticals Inc   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chemokine; Combinatorial chemistry; CXCR3 receptor antagonists; Piperazinyl piperidine; Solid phase synthesis

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR3 ANTAGONIST; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; REACTION ANALYSIS; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ANTI-INFLAMMATORY AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; HUMANS; PIPERAZINES; PIPERIDINES; RECEPTORS, CXCR3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 68349137669     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.020     Document Type: Article

References (26)

1. Liu L., Callahan M.K., Huang D., and Ransohoff R.M. Curr. Top. Dev. Biol. 68 (2005) 149
2. Turner J.E., Steinmetz O.M., Stahl R.A., and Panzer U. Mini-Rev. Med. Chem. 7 (2007) 1089
3. Szczuciński A., and Losy J. Acta Neurol. Scand. 115 (2007) 137
4. Rottman J.B., Smith T.L., Ganley K.G., Kikuchi T., and Krueger J.G. Lab. Invest. 81 (2001) 355
5. For alternative views on the role of CXCR3 in allograft rejection see:. Hancock W.W., Lu B., Gao W., Csizmadia V., Faia K., King J.A., Smiley S.T., Ling M., Gerard N.P., and Gerard C. J. Exp. Med. 192 (2000) 1515
6. Zerwes H.-G., Li J., Kovarik J., Streiff M., Hofmann M., Roth L., Luyten M., Pally C., Loewe R.P., Wieczorek G., Banteli R., Thoma G., and Luckow B. Am. J. Transplant. 8 (2008) 1604
7. Schnickel G.T., Bastani S., Hsieh G.R., Shefizadeh A., Bhatia R., Fishbein M.C., Belperio J., and Ardehali A. J. Immunol. 180 (2008) 4714
8. For reviews of small molecule CXCR3 antagonists see:. Wijtmans M., Verzijl D., Leurs R., de Esch I.J.P., and Smit M.J. ChemMedChem 3 (2008) 861
9. Collins T.L., Johnson M.G., and Medina J.C. Chemokine Biol. Basic Res. Clin. Appl. 2 (2007) 79
10. Medina J.C., Johnson M.G., and Collins T.L. Annu. Rep. Med. Chem. 40 (2005) 215
11. Johnson M., Li A., Liu J., Fu Z., Zhu L., Miao S., Wang X., Xu Q., Huang A., Marcus A., Xu F., Ebsworth K., Sablan E., Danao J., Kumer J., Dairaghi D., Lawrence C., Sullivan T., Tonn G., Schall T., Collins T., and Medina J. Bioorg. Med. Chem. Lett. 17 (2007) 3339
12. Hayes M.E., Breinlinger E.C., Wallace G.A., Grongsaard P., Miao W., McPherson M.J., Stoffel R.H., Green D.W., and Roth G.P. Bioorg. Med. Chem. Lett. 18 (2008) 2414
13. Cole A.G., Stroke I.L., Brescia M., Simhadri S., Zhang J.J., Hussain Z., Snider M., Haskell C., Ribeiro S., Appell K.C., Henderson I., and Webb M.L. Bioorg. Med. Chem. Lett. 16 (2006) 200
14. Knight R.L., Allen D.R., Birch H.L., Chapman G.A., Galvin F.C., Jopling L.A., Lock C.J., Meissner W.G., Owen D.A., Raphy G., Watson R.J., and Williams S.C. Bioorg. Med. Chem. Lett. 18 (2008) 629
15. Watson R.J., Allen D.R., Birch H.L., Chapman G.A., Galvin F.C., Jopling L.A., Knight R.L., Meier D., Meissner J.W.G., Oliver K., Owen D.A., Thomas E.J., Tremayne N., and Williams S.C. Bioorg. Med. Chem. Lett. 18 (2008) 147
16. Bongartz J.-P., Buntinx M., Coesemans E., Hermans B., Van Lommem G., and Van Wauwe J. Bioorg. Med. Chem. Lett. 18 (2008) 5819
17. Burbaum J.J., Ohlmeyer M.H.J., Reader J.C., Henderson I., Dillard L.W., Li G., Randle T.L., Sigal N.H., Chelsky D., and Baldwin J.J. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 6027
18. 50 values for chemotaxis induced by three ligands: 45 nM (vs 5 nM hIP-10), 20 nM (vs 50 nM hMIG), and 85 nM (vs 5 nM hI-TAC).
19. Jenh C.-H., Cox M.A., Hipkin W., Lu T., Pugliese-Sivo C., Gonsiorek W., Chou C.-C., Narula S.K., and Zavodny P.J. Cytokine 15 (2001) 113
20. 125I-IP10 was measured in a Wallac Microbeta. The values are reported as the mean of at least two determinations ± SD.
21. Rich D.H., and Gurwara S.K. J. Am. Chem. Soc. 97 (1975) 1575
22. All final compounds throughout the paper were purified by either silica gel chromatography or reverse-phase semi-preparative HPLC to a purity of at least 95%.
23. Wijtmans M., Verzijl D., van Dam C.M.E., Bosch L., Smit M.J., Leurs R., and de Esch I.J.P. Bioorg. Med. Chem. Lett. 19 (2009) 2252
24. Analog 21 was synthesized via the route outlined in Scheme 1 starting with 3-chloro-4-fluorobenzoic acid.
25. 3, 1,4-dioxane, 100 °C) of methyl 6-chloronicotinate with Boc-piperazine.
26. Compounds in Table 4 were synthesized via the route outlined in Scheme 1 starting with Boc-protected R and S 2-methylpiperazine.